Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Innovent Starts China Trials of Two Biologic Drug Candidates

publication date: Sep 15, 2016
Innovent Biologics of Suzhou announced clinical trial news for two of its biologic drugs: the company has started a pivotal China Phase III clinical trial of its Humira biosimilar, and it received CFDA approval to begin trials of its PD-1 candidate, which Innovent hopes will prove to be a best-in-class candidate. In the last twelve months, Innovent has been approved to start trials of four biologic drugs, a major achievement for the five-year old company. All together, Innovent is working on twelve biologics, a combination of biosimilar and novel molecules. More details....

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming event
Shanghai and Digital
May 10-14, 2021
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
The Ritz-Carlton Shanghai Pudong
March 23-25, 2021